Search

Search Constraints

You searched for: Author/Creator Mannent, Leda P.

Search Results

1. Dupilumab efficacy in chronic rhinosinusitis with nasal polyps from SINUS‐52 is unaffected by eosinophilic status. Issue 1 (4th June 2021)

2. Dupilumab improves health related quality of life: Results from the phase 3 SINUS studies. Issue 7 (1st February 2022)

3. Dupilumab improves health‐related quality of life in patients with chronic rhinosinusitis with nasal polyposis. Issue 1 (23rd October 2019)

4. Dupilumab in CRSwNP: Responder Analysis Using Clinically Meaningful Efficacy Outcome Thresholds. (24th November 2021)

5. Dupilumab reduces local type 2 pro‐inflammatory biomarkers in chronic rhinosinusitis with nasal polyposis. Issue 4 (21st January 2019)

6. Efficacy and safety of dupilumab in patients with uncontrolled severe chronic rhinosinusitis with nasal polyps and a clinical diagnosis of NSAID‐ERD: Results from two randomized placebo‐controlled phase 3 trials. Issue 4 (1st October 2021)

7. Efficacy of dupilumab in patients with a history of prior sinus surgery for chronic rhinosinusitis with nasal polyps. Issue 7 (21st February 2021)

8. Estimating Clinically Meaningful Change of Efficacy Outcomes in Inadequately Controlled Chronic Rhinosinusitis with Nasal Polyposis. (1st December 2021)